Sign inJoin waitlistJoin the waitlist

Martha Wadleigh

Medical Director, Inpatient Oncology · Mass General Brigham

Credentials: · · ·

History

Inpatient Oncology · Mass General Brigham
Present
Mass General Brigham
Present

Hematology and Medical Oncology
Dana-Farber Cancer Institute
2003–2006
Dana-Farber and Brigham and Women’s Hospital
2001–2003
Internal Medicine
Duke University Hospital
1998–2001
Duke University School of Medicine
1994–1998

Research

Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis
Cancer Cell · 2005 · 2,411 citations
MPLW515L is a novel somatic activating mutation in myelofibrosis with myeloid metaplasia
PLoS Medicine · 2006 · 1,170 citations
Acute myeloid leukemia ontogeny is defined by distinct somatic mutations
Blood · 2015 · 842 citations

Richard Stone
63 papers
Daniel DeAngelo
61 papers
DS
David Steensma
23 papers
Marlise Luskin
22 papers
IG
Ilene Galinsky
21 papers
Jacqueline Garcia
19 papers
Eric Winer
18 papers
GH
Gabriela Hobbs
16 papers
Ruben Mesa
16 papers
DG
Dwight Gilliland
15 papers
PA
Philip Amrein
15 papers
Ayalew Tefferi
14 papers

Clinical trials

Safety and Efficacy Study of CYT387 in Primary Myelofibrosis (PMF) or Post-polycythemia Vera (PV) or Post-essential Thrombocythemia (ET)
Principal investigator · Completed · Phase 1, Phase 2
Sierra Oncology LLC - a GSK company
2009–2012
A Phase 1/2 Study of Oral SB1518 in Subjects With Chronic Idiopathic Myelofibrosis
Principal investigator · Completed · Phase 1, Phase 2
S*BIO
2008–2012
Vaccine Therapy and Imatinib Mesylate in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia
Principal investigator · Completed · Phase 1
Dana-Farber Cancer Institute
2005–2020
Study of Cordycepin Plus Pentostatin in Patients With Refractory TdT-Positive Leukemia
Sub-investigator · Unknown · Phase 1, Phase 2
OncoVista, Inc.
2008–2010